Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antineoplastic Agents
  • Cancer Vaccines
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Immunoglobulin Idiotypes
  • Immunotherapy
  • Lymphoma, Follicular

abstract

  • TTP was shorter with mitumprotimut-T/GM-CSF compared with placebo/GM-CSF. This difference was possibly due to the imbalance in FLIPI scores.

publication date

  • June 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3646306

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.19.8903

PubMed ID

  • 19414675

Additional Document Info

start page

  • 3036

end page

  • 43

volume

  • 27

number

  • 18